Efficacy of telavancin against vancomycin-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model
Abstract number: P1910
Hegde S.S., Difuntorum S., Skinner R., Trumbull J., Krause K.M.
Objectives: Infections caused by Gram-positive organisms displaying intermediate susceptibility to glycopeptides such as vancomycin (VISA) are of significant concern in the medical community. Telavancin (TLV) is a novel lipoglycopeptide antibiotic that operates through a unique, multifunctional mechanism of action to produce potent, rapid bactericidal activity against resistant Gram-positive pathogens, including VISA. The goal of the present study was to compare the efficacy of TLV with vancomycin (VAN) in a murine model of VISA-induced bacteraemia.
Methods: Immunocompromised mice (female non-Swiss albino, 1825 g) were inoculated intraperitoneally with VISA HIP5836 (107 colony-forming units per mL). Starting 4 hours post-inoculation, mice received two subcutaneous doses (once every 12 hours) of vehicle, TLV or VAN. Mouse pharmacokinetic data were generated and used to select doses of TLV (40 mg/kg) and VAN (110 mg/kg) that equated to clinical exposures. Reductions in bacterial titre (in blood and spleen) at 12, 24 and 48 hours post-treatment were quantified.
Results: Telavancin demonstrated potent antibacterial activity against VISA strain HIP5836 in vitro in terms of MIC and in vivo in terms of reduction in blood and spleen bacterial titres compared with vancomycin (Table).
Table. MICs and blood and spleen bacterial titres
Conclusions: TLV is more efficacious than VAN in a mouse model of VISA bacteraemia infection.
|Session name:||18th European Congress of Clinical Microbiology and Infectious Diseases|
|Back to top|